PMV Pharmaceuticals, Inc. (PMVP)
NASDAQ: PMVP · Real-Time Price · USD
1.100
-0.010 (-0.90%)
Mar 31, 2025, 1:17 PM EDT - Market open
PMV Pharmaceuticals Employees
PMV Pharmaceuticals had 47 employees as of December 31, 2024. The number of employees decreased by 16 or -25.40% compared to the previous year.
Employees
47
Change (1Y)
-16
Growth (1Y)
-25.40%
Revenue / Employee
n/a
Profits / Employee
-$1,249,128
Market Cap
57.13M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 47 | -16 | -25.40% |
Dec 31, 2023 | 63 | 1 | 1.61% |
Dec 31, 2022 | 62 | 8 | 14.81% |
Dec 31, 2021 | 54 | 10 | 22.73% |
Dec 31, 2020 | 44 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PMVP News
- 4 weeks ago - PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 6 weeks ago - PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 10 months ago - Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator - Business Wire
- 11 months ago - PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights - GlobeNewsWire
- 1 year ago - PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway - GlobeNewsWire